

# Premature Ejaculation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/PFF776E8172EEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: PFF776E8172EEN

## Abstracts

The 7 major premature ejaculation markets reached a value of US\$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 5.3 Billion by 2034, exhibiting a growth rate (CAGR) of 7.64% during 2024-2034.

The premature ejaculation market has been comprehensively analyzed in IMARC's new report titled "Premature Ejaculation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Premature ejaculation refers to a common sexual health concern that affects many men, characterized by the inability to control ejaculation during sexual activity. It is defined as the occurrence of ejaculation before or shortly after penetration, often leading to dissatisfaction for both partners. This condition may cause emotional distress, relationship strain, and reduced self-esteem. The symptoms of the illness include consistent ejaculation within first minute of penetration or even before penetration occurs. While occasional instances of early ejaculation might not necessarily indicate a problem, persistent and recurrent occurrences could point to the presence of the disease. Individuals suffering from the ailment might also experience psychological factors, such as stress, performance pressure, and anxiety. Diagnosing premature ejaculation involves a thorough medical history and a discussion of sexual habits with a healthcare provider. The Intravaginal Ejaculatory Latency Time (IELT) is commonly used as a quantitative measure, representing the time from penetration to ejaculation to confirm the diagnosis.

The increasing prevalence of various psychological factors associated with the ailment, such as early sexual experiences, sexual abuse, poor body image, depression, anxiety, etc., is primarily driving the premature ejaculation market. In addition to this, the rising incidence of irregular hormone levels, which affect rhythmic muscle contraction and

regulate orgasm via peripheral, central, and spinal mechanisms, is also creating a positive outlook for the market. Moreover, the inflating application of effective medications, including selective serotonin reuptake inhibitors and topical anesthetics, to manage the condition and prolong ejaculation is further bolstering the market growth. Apart from this, the widespread adoption of counseling and sex therapy as viable approaches to address the emotional dimensions associated with premature ejaculation is acting as another significant growth-inducing factor. Additionally, the emerging popularity of behavioral techniques on account of their numerous advantages, like non-invasiveness, improved control over ejaculation timing, enhancing overall sexual satisfaction for both partners, etc., is also augmenting the market growth. Furthermore, the escalating demand for dorsal neurectomy procedures that involve cutting or removing a portion of the dorsal nerve responsible for transmitting sensory signals from the penis to the brain is expected to drive the premature ejaculation market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the premature ejaculation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for premature ejaculation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the premature ejaculation market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the premature ejaculation market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the premature ejaculation market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current premature ejaculation marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

*Premature Ejaculation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 20...*

## Market Insights

How has the premature ejaculation market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the premature ejaculation market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the premature ejaculation market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of premature ejaculation across the seven major markets?

What is the number of prevalent cases (2018-2034) of premature ejaculation by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of premature ejaculation by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with premature ejaculation across the seven major markets?

What is the size of the premature ejaculation patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of premature ejaculation?

What will be the growth rate of patients across the seven major markets?

## Premature Ejaculation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for premature ejaculation drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the premature ejaculation market?

What are the key regulatory events related to the premature ejaculation market?

What is the structure of clinical trial landscape by status related to the premature ejaculation market?

What is the structure of clinical trial landscape by phase related to the premature ejaculation market?

What is the structure of clinical trial landscape by route of administration related to the premature ejaculation market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 PREMATURE EJACULATION - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 PREMATURE EJACULATION - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 PREMATURE EJACULATION - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 PREMATURE EJACULATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 PREMATURE EJACULATION - UNMET NEEDS**

## **10 PREMATURE EJACULATION - KEY ENDPOINTS OF TREATMENT**

## **11 PREMATURE EJACULATION - MARKETED PRODUCTS**

- 11.1 List of Premature Ejaculation Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Fortacin (Lidocaine/prilocaine) - Plethora Solutions
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 PREMATURE EJACULATION - PIPELINE DRUGS**

### 12.1 List of Premature Ejaculation Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Cligosiban - Ixchelsis
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. PREMATURE EJACULATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. PREMATURE EJACULATION – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 PREMATURE EJACULATION - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Premature Ejaculation - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Premature Ejaculation - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Premature Ejaculation - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Premature Ejaculation - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)

- 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Premature Ejaculation - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Premature Ejaculation - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Premature Ejaculation - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Premature Ejaculation - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Premature Ejaculation - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Premature Ejaculation - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Premature Ejaculation - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Premature Ejaculation - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Premature Ejaculation - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Premature Ejaculation - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Premature Ejaculation - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Premature Ejaculation - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Premature Ejaculation - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Premature Ejaculation - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Premature Ejaculation - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Premature Ejaculation - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Premature Ejaculation - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Premature Ejaculation - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Premature Ejaculation - Access and Reimbursement Overview

## **16 PREMATURE EJACULATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 PREMATURE EJACULATION MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 PREMATURE EJACULATION MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Premature Ejaculation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/PFF776E8172EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFF776E8172EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

